A. Tsuburaya

发表

Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial

T. Yoshikawa, J. Sakamoto, K. Tanabe, 2013, Annals of Surgical Oncology.

Updated result on the 2.5-year follow-up of GC0301/TOP-002: Randomized phase III study of irinotecan plus S-1 (IRI-S) versus S-1 alone as first-line treatment for advanced gastric cancer (AGC).

H. Imamura, H. Narahara, Y. Sakata, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.